2025-11-05
7 分钟Hey listeners, it's Tuesday, November 4th.
I'm David Wehner for The Wall Street Journal, and this is What's News in Earnings,
our look at some of the biggest themes standing out this earnings season.
In the pharma world, there's Eli Lilly, and then there's pretty much everyone else.
Lilly's weight loss powerhouse continues to reshape the industry,
with sales of its GLP-1 drugs like Zephound Soaring, and rivals scrambling to respond.
In the latest twist and the sign of just how fierce the new obesity drug arms race has become,
the maker of Ozempic, Novo Nordisk,
is now trying to snatch away another company in the space, Metzera, from Pfizer.
At the same time,
farmers' negotiations with President Trump over drug prices and import tariffs are hanging over the sector,
testing how companies will deliver growth,
even as blockbusters like Ketruda from Merck edge toward patent expiration,
while others like Humira from Abvi already have.
We're joined by Wall Street Journal reporter Peter Loftus who's been tracking pharma for us.
Peter, there's a lot of hype baked into this whole GLP One boom.
What did we learn from Eli Lilly's earnings last week?
Is this a sustainable growth story or are we in kind of a bubble?
Well,
we learned from Eli Lilly that when you have a couple of drugs that are in demand